Viracta Therapeutics, Inc. (VIRX)

Viracta Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	12.32	36.77	103.55	47.09	18.26
Short-Term Investments	41.37	54.27	0	0	16.36
Cash & Cash Equivalents	53.69	91.04	103.55	47.09	34.63
Cash Growth	-41.03%	-12.08%	119.91%	36.00%	152.81%
Other Current Assets	1.27	2.7	1.72	0.11	1.7
Total Current Assets	54.96	93.75	105.27	47.2	36.32
Property, Plant & Equipment	0.46	0.41	0.88	1.03	0.82
Other Long-Term Assets	1.26	1.83	2.4	0.08	0.1
Total Long-Term Assets	1.73	2.24	3.28	1.11	0.92
Total Assets	56.69	95.99	108.55	48.31	37.24
Accounts Payable	2.44	2.54	2.9	1.56	0.79
Current Debt	25.56	0.28	0.38	1.37	6.01
Other Current Liabilities	10.38	7.19	5.8	3.36	2.62
Total Current Liabilities	38.37	10.01	9.08	6.28	9.42
Long-Term Debt	0	24.88	5.1	4.81	0.27
Other Long-Term Liabilities	0	0	0	83.41	0.01
Total Long-Term Liabilities	0	24.88	5.1	88.22	0.28
Total Liabilities	38.37	34.89	14.18	94.51	9.7
Total Debt	25.56	25.16	5.48	6.18	6.28
Debt Growth	1.59%	359.20%	-11.33%	-1.66%	-15.06%
Retained Earnings	-265.93	-214.87	-165.68	-50.92	-682.8
Comprehensive Income	0.01	-0.18	0	0	0
Shareholders' Equity	18.32	61.1	94.37	-46.2	27.54
Net Cash / Debt	28.14	65.89	98.08	40.91	28.34
Net Cash / Debt Growth	-57.30%	-32.82%	139.73%	44.34%	349.89%
Net Cash Per Share	0.73	1.74	3.08	125.99	11.39
Working Capital	16.59	83.74	96.19	40.92	26.91
Book Value Per Share	0.47	1.62	2.96	-142.27	11.06

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).